These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38300235)

  • 1. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
    Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
    Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
    Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
    Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
    Turkoz I; Wong J; Chee B; Siddiqui U; Knight RK; Richarz U; Correll CU
    Ther Adv Psychopharmacol; 2023; 13():20451253231200258. PubMed ID: 37786804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
    Wang GH; Svensson M; Shao H; Vouri SM; Park H
    J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
    Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
    Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
    Richarz U; Han J; Bai YM; Yu-Hai Chen E; Chung YC; Jhanwar VG; Kim SW; Sulaiman AH; Knight K; Gopal S
    Medicine (Baltimore); 2023 Aug; 102(34):e34623. PubMed ID: 37653768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults.
    Cirnigliaro G; Battini V; Castiglioni M; Renne M; Mosini G; Cheli S; Carnovale C; Dell'Osso B
    Expert Rev Neurother; 2024 Apr; 24(4):325-332. PubMed ID: 38445396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
    Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
    T'jollyn H; Russu A; Venkatasubramanian R; Gopal S; Nandy P; Neyens M; Faelens R; Samtani MN; Ackaert O; Perez-Ruixo JJ
    Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):477-489. PubMed ID: 38750386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
    T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
    Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
    Najarian D; Turkoz I; Knight RK; Galderisi S; Lamaison HF; Zalitacz P; Aravind S; Richarz U
    Int J Neuropsychopharmacol; 2023 Aug; 26(8):537-544. PubMed ID: 37480362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.
    Turkoz I; Daskiran M; Starr HL; Najarian D; Lopena O; Obando C; Keenan A; Benson C; Gopal S
    Neuropsychiatr Dis Treat; 2022; 18():1927-1937. PubMed ID: 36065384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
    Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
    J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database.
    Chiang CL; Chinen M; Daskiran M; Wakamatsu A; Turkoz I
    Neuropsychopharmacol Rep; 2024 Dec; 44(4):716-727. PubMed ID: 39259889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.